ToxSci Advance Access originally published online on August 27, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences 76, 220-228 (2003)
Copyright © 2003 by the Society of Toxicology
SYSTEMS TOXICOLOGY |
Evaluation of Hepatotoxic Potential of Drugs by Inhibition of Bile-Acid Transport in Cultured Primary Human Hepatocytes and Intact Rats
* Department of Drug Safety Evaluation, Pfizer Global Research and Development, Ann Arbor, Michigan 48105;
University of Pittsburgh Medical Center, Department of Pathology, Pittsburgh, Pennsylvania 15261;
Departments of Pharmokinetics, Dynamics, and Metabolism and
Pharmaceutical Sciences, Prizer Global Research and Development, Ann Arbor, Michigan 48105;
¶ Veterans Administration Medical Center, White River Junction, Vermont 05009; and
|| Departments of Biochemistry and Pharmacology/Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03756
Inhibition of canalicular bile acid efflux by medications is associated with clinical liver toxicity, sometimes in the absence of major liver effects in experimental species. To predict the hepatotoxic potential of compounds in vitro and in vivo, we investigated the effect of clinical cholestatic agents on [3H]taurocholic acid transport in regular and collagen-sandwich cultured human hepatocytes. Hepatocytes established a well-developed canalicular network with bile acid accumulating in the canalicular lumen within 15 min of addition to cells. Removing Ca2+ and Mg2+ from the incubation buffer destroyed canalicular junctions, resulting in bile acid efflux into the incubation buffer. Canalicular transport was calculated based on the difference between the amount of bile acid effluxed into the Ca/Mg2+-free and regular buffers with linear efflux up to 10 min. Hepatocytes cultured in the nonsandwich configuration also transported taurocholic acid, but at 50% the rate in sandwiched cultures. Cyclosporin A, bosentan, CI-1034, glyburide, erythromycin estolate, and troleandomycin inhibited efflux in a concentration-dependent manner. In contrast, new generation macrolide antibiotics with lower incidence of clinical hepatotoxicity were much less potent inhibitors of efflux. An in vivo study was conducted whereby glyburide or CI-1034, administered iv to male rats, produced a 2.4-fold increase in rat total serum bile acids. A synergistic 6.8-fold increase in serum total bile acids was found when both drugs were delivered together. These results provide methods to evaluate inhibitory effects of potentially cholestatic compounds on bile-acid transport, and to rank compounds according to their hepatotoxic potential.
Key Words: cholestasis; preclinical; clinical; toxicity; hepatocytes; bile acids; macrolides; transport.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Kis, E. Ioja, T. Nagy, L. Szente, K. Heredi-Szabo, and P. Krajcsi Effect of Membrane Cholesterol on BSEP/Bsep Activity: Species Specificity Studies for Substrates and Inhibitors Drug Metab. Dispos., September 1, 2009; 37(9): 1878 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Feng, J. J. Xu, Y.-A. Bi, R. Mireles, R. Davidson, D. B. Duignan, S. Campbell, V. E. Kostrubsky, M. C. Dunn, A. R. Smith, et al. Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714 Toxicol. Sci., April 1, 2009; 108(2): 492 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-w. Ye, P. Augustijns, and P. Annaert Cellular Accumulation of Cholyl-Glycylamido-Fluorescein in Sandwich-Cultured Rat Hepatocytes: Kinetic Characterization, Transport Mechanisms, and Effect of Human Immunodeficiency Virus Protease Inhibitors Drug Metab. Dispos., July 1, 2008; 36(7): 1315 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lang, M. Haberl, D. Jung, A. Drescher, R. Schlagenhaufer, A. Keil, E. Mornhinweg, B. Stieger, G. A. Kullak-Ublick, and R. Kerb Genetic Variability, Haplotype Structures, and Ethnic Diversity of Hepatic Transporters MDR3 (ABCB4) and Bile Salt Export Pump (ABCB11) Drug Metab. Dispos., September 1, 2006; 34(9): 1582 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. McRae, C. M. Lowe, X. Tian, D. L. Bourdet, R. H. Ho, B. F. Leake, R. B. Kim, K. L. R. Brouwer, and A. D. M. Kashuba Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1068 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Turncliff, K. A. Hoffmaster, J. C. Kalvass, G. M. Pollack, and K. L. R. Brouwer Hepatobiliary Disposition of a Drug/Metabolite Pair: Comprehensive Pharmacokinetic Modeling in Sandwich-Cultured Rat Hepatocytes J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kostrubsky, S. C. Strom, A. S. Kalgutkar, S. Kulkarni, J. Atherton, R. Mireles, B. Feng, R. Kubik, J. Hanson, E. Urda, et al. Inhibition of Hepatobiliary Transport as a Predictive Method for Clinical Hepatotoxicity of Nefazodone Toxicol. Sci., April 1, 2006; 90(2): 451 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lengyel, Z. Veres, P. Szabo, L. Vereczkey, and K. Jemnitz CANALICULAR AND SINUSOIDAL DISPOSITION OF BILIRUBIN MONO- AND DIGLUCURONIDES IN SANDWICH-CULTURED HUMAN AND RAT PRIMARY HEPATOCYTES Drug Metab. Dispos., September 1, 2005; 33(9): 1355 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kostrubsky, J. F. Sinclair, S. C. Strom, S. Wood, E. Urda, D. B. Stolz, Y. H. Wen, S. Kulkarni, and A. Mutlib Phenobarbital and Phenytoin Increased Acetaminophen Hepatotoxicity Due to Inhibition of UDP-Glucuronosyltransferases in Cultured Human Hepatocytes Toxicol. Sci., September 1, 2005; 87(1): 146 - 155. [Abstract] [Full Text] [PDF]
|
|